Tag Archives: Agios Pharmaceuticals

November, 2018

16 November
Agios Presents Updated Data from Phase 1 Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma

NEW ORLEANS, Nov. 16, 2018 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented updated data from the ongoing Phase 1 study evaluating single agent AG-881 in advanced glioma. The data were featured in an …
Share

1 March
Celgene, Agios Gain FDA Priority Review for Enasidenib for Treatment of Acute Myeloid Leukemia

SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals (NASDAQ:AGIO) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s New Drug Application (NDA) for enasidenib (AG-221/CC-90007) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase …
Share

12 October
Celgene and Agios Collaborate with Abbott for Diagnostics Identification of IDH Mutations in AML

SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced each company has entered into collaboration agreements with Abbott (NYSE: ABT), a leader in diagnostic technologies, to develop and commercialize companion diagnostic tests on Abbott’s m2000 RealTime System to identify isocitrate dehydrogenase (IDH) mutations in …
Share

29 April
Celgene Inks Cancer Deals with Agios Pharmaceuticals and Northern Biologics

Celgene is enhancing its oncology pipeline, striking separate cancer-focused deals with Agios Pharmaceuticals and startup Northern Biologics. Agios announced it is expanding its partnership with cancer metabolism partner Celgene. The companies have entered into a new joint worldwide development and profit share collaboration for AG-881, a small molecule that has …
Share